Treatment of cardiovascular disease using ActRII ligand traps

Patent metadata

Field	Value
Publication number	US-11813308-B2
Application number	US-201515517782-A
Country	US
Kind code	B2
Filing date	Oct 8, 2015
Priority date	Oct 9, 2014
Publication date	Nov 14, 2023
Grant date	Nov 14, 2023

Abstract

Provided herein are methods of treating diseases associated with vascular calcification and/or cardiovascular disease in a subject by using the level of a biomarker, in particular, snail homolog 1 (Snai1), phosphosmad2, phosphosmad3, urinary protein, dickkopf homolog 1 (Dkk1), collagen type 1 alpha 1 (Col1a1), activin (e.g., free activin), runt-related transcription factor 2 (Runx2), alkaline phosphatase (Alp), bone-specific alkaline phosphatase (BSAP), C-terminal type 1 collagen telopeptide (CTX), osterix, Klotho, alpha-smooth muscle actin (alpha-SMA), myocardin (MYOCD), activin receptor type 2A (ActRIIA), axis inhibition protein 2 (Axin2), and/or smooth muscle protein 22-alpha (Sm22-alpha), as an indicator(s) of responsiveness of the subject to the treatment, efficacy of the treatment, or appropriate dosage for the treatment with an activin type II receptor signaling inhibitor. Provided herein are methods of bone resorption in a subject by using the level of a biomarker, in particular, snail homolog 1 (Snai1), phosphosmad2, phosphosmad3, urinary protein, dickkopf homolog 1 (Dkk1), collagen type 1 alpha 1 (Col1a1), activin (e.g., free activin), runt-related transcription factor 2 (Runx2), alkaline phosphatase (Alp), bone-specific alkaline phosphatase (BSAP), c-terminal telopeptide (CTX), osterix, Klotho, alpha-smooth muscle actin (alpha-SMA), myocardin (MYOCD), activin receptor type 2A (ActRIIA), axis inhibition protein 2 (Axin2), and/or smooth muscle protein 22-alpha (Sm22-alpha), as an indicator(s) of responsiveness of the subject to the treatment, efficacy of the treatment, or appropriate dosage for the treatment with an activin type II receptor signaling inhibitor.

First claim

What is claimed:

1. A method for treating a disease in a subject, comprising administering to the subject a pharmaceutically effective dose of an activin receptor type II (ActRII) signaling inhibitor, wherein the subject has:
(a) elevated levels of snail homolog 1 (Snai1) as compared to levels of Snai1 in a reference population;
(b) decreased levels of alpha smooth muscle actin (alpha-SMA) as compared to levels of alpha-SMA in a reference population;
(c) elevated levels of urinary protein as compared to levels of urinary protein in a reference population; and/or
(d) decreased levels of Axin2 as compared to levels of Axin2 in a reference population,
wherein the disease is:
(a) cardiovascular disease;
(b) vascular calcification;
(c) cardiovascular disease associated with and/or resulting from vascular calcification;
(d) arterial stiffness;
(e) cardiovascular disease associated with and/or resulting from arterial stiffness;
(f) left ventricular hypertrophy (LVH);
(g) cardiovascular disease associated with and/or resulting from left ventricular hypertrophy;
(h) cardiovascular disease associated with and/or resulting from renal disease; or
(i) bone resorption associated with chronic kidney disease-mineral and bone disease (CKD-MBD), and
wherein said ActRII signaling inhibitor comprises an amino acid sequence that is
(a) at least 98% identical to SEQ ID NO:2;
(b) at least 98% identical to SEQ ID NO:3;
(c) at least 98% identical to SEQ ID NO:6;
(d) at least 98% identical to SEQ ID NO:7; or
(e) at least 98% identical to SEQ ID NO:12.

2. The method of claim 1 , wherein the pharmaceutically effective dose of the ActRII signaling inhibitor is about 15 mg, about 30 mg, about 45 mg, about 60 mg, about 75 mg, about 90 mg, or about 1 g or about 0.1 mg/kg, about 0.13 mg/kg, about 0.2 mg/kg, about 0.26 mg/kg, about 0.3 mg/kg, about 0.4 mg/kg, about 0.5 mg/kg, about 0.6 mg/kg, about 0.7 mg/kg, about 0.8 mg/kg, about 0.9 mg/kg, about 1.0 mg/kg, about 1.1 mg/kg, about 1.2 mg/kg, about 1.3 mg/kg, about 1.4 mg/kg, or about 1.5 mg/kg.

3. The method of claim 1 , wherein the elevated levels of Snai1, and/or urinary protein, are about 10%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80% 90%, 100%, 200%, or 500% greater than the levels of Snai1, and/or urinary protein, respectively, in the reference population.

4. The method of claim 1 , wherein the decreased levels of alpha-SMA, and/or Axin2 are about 10%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, or 90% less than the levels of alpha-SMA, and/or Axin2 respectively, in the reference population.

5. A method for treating a disease in a subject, wherein the method comprises:
(a) administering to the subject an initial dose of an ActRII signaling inhibitor to the subject;
(b) taking a first measurement of the level of Snai1, urinary protein, alpha-SMA, and/or Axin2 in the subject;
(c) after a period of time, taking a second measurement of the level of Snai1, urinary protein, alpha-SMA, and/or Axin2 in the subject; and
(d) administering to the subject an adjusted dose of the activin receptor type II signaling inhibitor, wherein the adjusted dose is based on the detected change between the first measurement and the second measurement, thereby treating and/or preventing said disease;
wherein said disease is:
(a) cardiovascular disease;
(b) vascular calcification;
(c) cardiovascular disease associated with and/or resulting from vascular calcification;
(d) arterial stiffness;
(e) cardiovascular disease associated with and/or resulting from arterial stiffness;
(f) left ventricular hypertrophy (LVH);
(g) cardiovascular disease associated with and/or resulting from left ventricular hypertrophy;
(h) cardiovascular disease associated with and/or resulting from renal disease; or
(i) bone resorption associated with CKD-MBD; and
wherein said ActRII signaling inhibitor comprises an amino acid sequence that is
(a) at least 98% identical to SEQ ID NO:2;
(b) at least 98% identical to SEQ ID NO:3;
(c) at least 98% identical to SEQ ID NO:6;
(d) at least 98% identical to SEQ ID NO:7; or
(e) at least 98% identical to SEQ ID NO:12.

6. The method of claim 5 , wherein the initial dose of the ActRII signaling inhibitor is about 15 mg, about 30 mg, about 45 mg, about 60 mg, about 75 mg, about 90 mg, or about 1 g or about 0.1 mg/kg, about 0.13 mg/kg, about 0.2 mg/kg, about 0.26 mg/kg, about 0.3 mg/kg, about 0.4 mg/kg, about 0.5 mg/kg, about 0.6 mg/kg, about 0.7 mg/kg, about 0.8 mg/kg, about 0.9 mg/kg, about 1.0 mg/kg, about 1.1 mg/kg, about 1.2 mg/kg, about 1.3 mg/kg, about 1.4 mg/kg, or about 1.5 mg/kg.

7. The method of claim 5 , wherein the adjusted dose of the ActRII signaling inhibitor is greater than the initial dose if:
(a) the level of Snai1 is elevated as compared to the level of Snai1 in a reference population;
(b) the level of alpha-SMA is decreased as compared to the level of alpha-SMA in a reference population;
(c) the level of urinary protein is elevated as compared to the level of urinary protein in a reference population; and/or
(d) the level of Axin2 is decreased compared to the level of Axin2 in a reference population.

8. The method of claim 7 , wherein the adjusted dose is about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, or about 35 mg greater than the initial dose, or about 0.05 mg/kg, about 0.1 mg/kg, about 0.15 mg/kg, about 0.25 mg/kg, about 0.3 mg/kg, about 0.35 mg/kg, about 0.4 mg/kg, or about 0.5 mg/kg greater than the initial dose.

9. The method of claim 5 , wherein the adjusted dose of the ActRII signaling inhibitor is less than the initial dose if:
(a) the level of Snai1 is decreased as compared to the level of Snai1 in a reference population;
(b) the level of alpha-SMA is elevated as compared to the level of alpha-SMA in a reference population;
(c) the level of urinary protein is decreased as compared to the level of urinary protein in a reference population; and/or
(d) the level of Axin2 is elevated as compared to the level of Axin2 in a reference population.

10. The method of claim 9 , wherein the adjusted dose is about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, or about 35 mg less than the initial dose, or about 0.05 mg/kg, about 0.1 mg/kg, about 0.15 mg/kg, about 0.25 mg/kg, about 0.3 mg/kg, about 0.35 mg/kg, about 0.4 mg/kg, or about 0.5 mg/kg less than the initial dose.

11. The method of claim 5 , wherein
(a) the first measurement is taken prior to the commencement of the treatment;
(b) the first measurement is taken immediately after commencement of the treatment or within at most 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 1 week, 2 weeks, 3 weeks, 4 weeks, or 2 months thereof; or
(c) the second measurement is taken immediately after commencement of the treatment or within at most 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 1 week, 2 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months thereof.

12. The method of claim 7 , wherein
(a) the elevated levels of Snai1, and/or urinary protein, are about 10%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, 100%, 200%, or 500% greater than the levels of Snai1, and/or urinary protein, respectively, in the reference population; and/or
(b) the decreased levels of alpha-SMA, and/or Axin2 are about 10%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, or 90% less than the levels of alpha-SMA, and/or Axin2 respectively, in a reference population.

13. The method of claim 9 , wherein
(a) the elevated levels of alpha-SMA, and/or Axin2 are about 10%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80% 90%, 10

Assignees

• Celgene Corp
• Washington University St Louis

Inventors

• Hruska Keith
• Fang Yifu
• Smith William
• Chen Nianhang

Classifications

• A61K38/179 Primary

  for growth factors; for growth regulators · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P19/10

  for osteoporosis · CPC title

• C07K14/71

  for growth factors; for growth regulators · CPC title